Free Trial

Sage Therapeutics (SAGE) Stock Price, News & Analysis

$10.02
-0.36 (-3.47%)
(As of 09:34 AM ET)
Today's Range
$9.73
$10.06
50-Day Range
$10.38
$13.08
52-Week Range
$9.73
$41.67
Volume
79,517 shs
Average Volume
1.10 million shs
Market Capitalization
$603.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.45

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.05 Rating Score
Upside/​Downside
228.0% Upside
$34.05 Price Target
Short Interest
Healthy
11.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.64
Upright™ Environmental Score
News Sentiment
0.05mentions of Sage Therapeutics in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.54) to ($5.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.47 out of 5 stars

Medical Sector

101st out of 901 stocks

Pharmaceutical Preparations Industry

38th out of 426 stocks

SAGE stock logo

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

SAGE Stock News Headlines

625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
Sage Therapeutics Stock Slides as Pipeline Thins
625,000% Gain
Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.
TD Cowen Keeps Their Buy Rating on SAGE Therapeutics (SAGE)
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Update
See More Headlines
Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
7/25/2024
Next Earnings (Confirmed)
7/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SAGE
Employees
487
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.45
High Stock Price Target
$294.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+231.9%
Consensus Rating
Hold
Rating Score (0-4)
2.05
Research Coverage
20 Analysts

Profitability

Net Income
$-541,490,000.00
Net Margins
-552.52%
Pretax Margin
-552.52%

Debt

Sales & Book Value

Annual Sales
$86.46 million
Book Value
$13.32 per share

Miscellaneous

Free Float
56,872,000
Market Cap
$624.67 million
Optionable
Optionable
Beta
0.90
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Barry E. GreeneMr. Barry E. Greene (Age 61)
    President, CEO & Director
    Comp: $1.29M
  • Ms. Kimi E. Iguchi CPA (Age 62)
    CFO & Treasurer
    Comp: $665.37k
  • Ms. Anne Marie Cook Esq. (Age 62)
    Senior VP, General Counsel & Secretary
    Comp: $711.6k
  • Mr. Christopher Benecchi (Age 52)
    Chief Business Officer
    Comp: $703.76k
  • Dr. Laura Gault M.D.
    Ph.D., Chief Medical Officer
  • Mr. Matt Lasmanis
    Chief Technology & Innovation Officer
  • Mr. Mike Quirk
    Chief Scientific Officer
  • Ashley Kaplowitz
    Director of Investor Relations
  • Ms. Erin E. Lanciani (Age 55)
    Chief People & Experience Officer
  • Dr. Amy Schacterle Ph.D.
    Senior Vice President of R&D Strategy and Business Management

SAGE Stock Analysis - Frequently Asked Questions

How have SAGE shares performed this year?

Sage Therapeutics' stock was trading at $21.67 at the beginning of the year. Since then, SAGE shares have decreased by 52.1% and is now trading at $10.38.
View the best growth stocks for 2024 here
.

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings data on Thursday, April, 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.63) by $0.17. The business's quarterly revenue was up 139.4% on a year-over-year basis.

Who are Sage Therapeutics' major shareholders?

Top institutional investors of Sage Therapeutics include Assenagon Asset Management S.A. (0.28%), Hennion & Walsh Asset Management Inc. (0.07%), Harbor Capital Advisors Inc. (0.06%) and Values First Advisors Inc. (0.05%). Insiders that own company stock include Barry E Greene, George Golumbeski and Elizabeth Barrett.
View institutional ownership trends
.

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Netflix (NFLX).

This page (NASDAQ:SAGE) was last updated on 7/25/2024 by MarketBeat.com Staff

From Our Partners